Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14146263 | 1.00 | LMNA (0.35) | LMNACYP2C9SMN1; SMN2ATMDPP4 | |
| SCHEMBL6615446 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2GAA | |
| SCHEMBL23525415 | 0.82 | ATM (0.46) | LMNACYP2C9ATM | |
| SCHEMBL13225674 | 0.82 | ATM (0.37) | LMNACYP2C9ATM | |
| SCHEMBL14077908 | 0.82 | ATM (0.46) | LMNACYP2C9ATM | |
| SCHEMBL8055442 | 0.81 | — | — | |
| SCHEMBL9020278 | 0.81 | — | — | |
| SCHEMBL16003095 | 0.81 | — | — | |
| SCHEMBL14077824 | 0.79 | ATM (0.42) | ATMDPP4DPP7 | |
| SCHEMBL14077834 | 0.79 | ATM (0.42) | ATMDPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | LMNA 2647/4885CYP2C9 4866/4885SMN1; SMN2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.